tetano
Editor, Senior Moderator
CPT Pharmacometrics Syst Pharmacol. 2020 Mar 20. doi: 10.1002/psp4.12510. [Epub ahead of print]
Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials.
Madelain V[SUP]1[/SUP], Mentr? F[SUP]1[/SUP], Baize S[SUP]2[/SUP], Anglaret X[SUP]3,[/SUP][SUP]4[/SUP], Laou?nan C[SUP]1[/SUP], Oestereich L[SUP]5,[/SUP][SUP]6[/SUP], Nguyen THT[SUP]1[/SUP], Malvy D[SUP]3,[/SUP][SUP]7[/SUP], Piorkowski G[SUP]8[/SUP], Graw F[SUP]9[/SUP], G?nther S[SUP]5,[/SUP][SUP]6[/SUP], Raoul H[SUP]10[/SUP], de Lamballerie X[SUP]8[/SUP], Guedj J[SUP]1[/SUP]; Reaction! research group.
Author information
Abstract
In 2014, our research network was involved in the evaluation of favipiravir, an anti-Influenza polymerase inhibitor, against Ebola virus. In this review we discuss how mathematical modelling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a non-human primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions between the virus, the innate and adaptive immune response and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
This article is protected by copyright. All rights reserved.
PMID:32198838DOI:10.1002/psp4.12510
Free full text
Modeling favipiravir antiviral efficacy against emerging viruses: from animal studies to clinical trials.
Madelain V[SUP]1[/SUP], Mentr? F[SUP]1[/SUP], Baize S[SUP]2[/SUP], Anglaret X[SUP]3,[/SUP][SUP]4[/SUP], Laou?nan C[SUP]1[/SUP], Oestereich L[SUP]5,[/SUP][SUP]6[/SUP], Nguyen THT[SUP]1[/SUP], Malvy D[SUP]3,[/SUP][SUP]7[/SUP], Piorkowski G[SUP]8[/SUP], Graw F[SUP]9[/SUP], G?nther S[SUP]5,[/SUP][SUP]6[/SUP], Raoul H[SUP]10[/SUP], de Lamballerie X[SUP]8[/SUP], Guedj J[SUP]1[/SUP]; Reaction! research group.
Author information
Abstract
In 2014, our research network was involved in the evaluation of favipiravir, an anti-Influenza polymerase inhibitor, against Ebola virus. In this review we discuss how mathematical modelling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a non-human primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions between the virus, the innate and adaptive immune response and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
This article is protected by copyright. All rights reserved.
PMID:32198838DOI:10.1002/psp4.12510
Free full text